Single-Center Experience with the Bicarbon Bileaflet Prosthetic Heart Valve in Japan

: We analyzed midterm results using the Bicarbon valve in a single center. Forty‐four patients had aortic valve replacement (AVR), 48 had mitral valve replacement (MVR), and 13 had both aortic and mitral valve replacement (DVR). The mean age of the 105 patients was 61.2 ± 11.3 years. The mean follow...

Full description

Saved in:
Bibliographic Details
Published in:Artificial organs 2002-10, Vol.26 (10), p.856-861
Main Authors: Misawa, Yoshio, Saito, Tsutomu, Konishi, Hiroaki, Oki, Shin-ichi, Kaminishi, Yuichiro, Tezuka, Yasuhiro, Aizawa, Kei, Takahashi, Hideki, Hasegawa, Nobuyuki, Kamisawa, Osamu, Kato, Morito, Fuse, Katsuo
Format: Article
Language:English
Subjects:
Aged
Aortic Valve - surgery
Bicarbon valve
Bileaflet prosthetic valve
Blood Vessel Prosthesis Implantation - adverse effects
Female
Follow-Up Studies
Heart valve disease
Heart Valve Diseases - mortality
Heart Valve Diseases - surgery
Heart Valve Prosthesis - adverse effects
Heart valve surgery
Humans
Japan
Male
Middle Aged
Mitral Valve - surgery
Postoperative Complications
Retrospective Studies
Survival Rate
Time Factors
Treatment Outcome
Valve replacement
Valve-related complication
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:: We analyzed midterm results using the Bicarbon valve in a single center. Forty‐four patients had aortic valve replacement (AVR), 48 had mitral valve replacement (MVR), and 13 had both aortic and mitral valve replacement (DVR). The mean age of the 105 patients was 61.2 ± 11.3 years. The mean follow‐up was 1.8 ± 1.1 years with a cumulative follow‐up of 188 patient‐years. There were 5 early deaths (4.7%: 4 in the AVR group and 1 in the MVR group) and 5 late deaths (2.7% per patient‐year: 3 malignancy, 1 cerebral hemorrhage, 1 myocardial infarction). Survival at 3 years was 91 ± 4% in the AVR group, 92 ± 5% in the MVR group, and 66 ± 23% in the DVR group. The linearized incidence of thromboembolic complications, hemorrhagic complications, and paravalvular leaks in all patients was 1.06 ± 2.34%, 1.60 ± 2.53%, and 0.53 ± 2.22% per patient‐year, respectively. No other complications were observed. In conclusion, the Bicarbon prosthetic heart valve has shown excellent clinical results associated with a low incidence of valve‐related complications.
ISSN:0160-564X
1525-1594
DOI:10.1046/j.1525-1594.2002.06987.x